Q8VC69 (S22A6_MOUSE) Reviewed, UniProtKB/Swiss-Prot
Last modified
April 3, 2013.
Version 95.
History...
Names·Attributes·General annotation·Ontologies·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize order
Names·Attributes·General annotation·Ontologies·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize orderNames and origin
| Protein names | Recommended name: Solute carrier family 22 member 6 Alternative name(s): Kidney-specific transport protein Novel kidney transcript Short name=mNKT Organic anion transporter 1 Renal organic anion transporter 1 Short name=mROAT1 | ||||
| Gene names |
| ||||
| Organism | Mus musculus (Mouse) [Reference proteome] | ||||
| Taxonomic identifier | 10090 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Glires › Rodentia › Sciurognathi › Muroidea › Muridae › Murinae › Mus › Mus![]() |
Protein attributes
| Sequence length | 545 AA. |
| Sequence status | Complete. |
| Protein existence | Evidence at protein level |
General annotation (Comments)
| Function | Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS), cidofovir, adefovir, 9-(2-phosphonylmethoxyethyl) guanine (PMEG), 9-(2-phosphonylmethoxyethyl) diaminopurine (PMEDAP), ochratoxin (OTA), acyclovir (ACV), 3'-azido-3-'deoxythymidine (AZT), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), hippurate (HA), indoleacetate (IA), indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) and edaravone sulfate By similarity. Mediates the sodium-independent uptake of p-aminohippurate (PAH). PAH uptake is inhibited by benzothiazolylcysteine (BTC), S-chlorotrifluoroethylcysteine (CTFC), cysteine S-conjugates S-dichlorovinylcysteine (DCVC), furosemide, steviol, phorbol 12-myristate 13-acetate (PMA), calcium ionophore A23187, benzylpenicillin, bumetamide, losartan, probenecid, phenol red, urate, glutarate and alpha-ketoglutarate By similarity. PAH uptake is inhibited by p-chloromercuribenzenesulphonate (PCMBS), diethyl pyrocarbonate (DEPC), indomethacin, sulindac, diclofenac, carprofen, okadaic acid and PKC activators. Ref.4 Ref.5 Ref.6 |
| Subcellular location | Cell membrane; Multi-pass membrane protein. Note: Localized to the plasma membrane. Ref.1 |
| Tissue specificity | Expressed in kidney; in the basolateral membrane and at much lower levels in brain. Ref.1 Ref.4 |
| Developmental stage | Developmentally regulated with significant expression beginning at E18 and rising just before birth. |
| Domain | Multiple cysteine residues are necessary for proper targeting to the plasma membrane. |
| Post-translational modification | Glycosylated. Glycosylation is necessary for proper targeting of the transporter to the plasma membrane. Ref.7 |
| Sequence similarities | Belongs to the major facilitator (TC 2.A.1) superfamily. Organic cation transporter (TC 2.A.1.19) family. [View classification] |
| Biophysicochemical properties | Kinetic parameters: KM=37.3 µM for PAH Ref.4 Vmax=210 pmol/min/mg enzyme for PAH uptake |
Ontologies
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||
Molecule processing | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 545 | 545 | Solute carrier family 22 member 6 | PRO_0000324168 | |||||
Regions | |||||||||
| Topological domain | 1 – 9 | 9 | Cytoplasmic Potential | ||||||
| Transmembrane | 10 – 30 | 21 | Helical; Potential | ||||||
| Topological domain | 31 – 129 | 99 | Extracellular Potential | ||||||
| Transmembrane | 130 – 150 | 21 | Helical; Potential | ||||||
| Topological domain | 151 – 157 | 7 | Cytoplasmic Potential | ||||||
| Transmembrane | 158 – 177 | 20 | Helical; Potential | ||||||
| Topological domain | 178 – 180 | 3 | Extracellular Potential | ||||||
| Transmembrane | 181 – 201 | 21 | Helical; Potential | ||||||
| Topological domain | 202 – 218 | 17 | Cytoplasmic Potential | ||||||
| Transmembrane | 219 – 239 | 21 | Helical; Potential | ||||||
| Topological domain | 240 – 242 | 3 | Extracellular Potential | ||||||
| Transmembrane | 243 – 263 | 21 | Helical; Potential | ||||||
| Topological domain | 264 – 331 | 68 | Cytoplasmic Potential | ||||||
| Transmembrane | 332 – 352 | 21 | Helical; Potential | ||||||
| Topological domain | 353 – 362 | 10 | Extracellular Potential | ||||||
| Transmembrane | 363 – 383 | 21 | Helical; Potential | ||||||
| Topological domain | 384 – 389 | 6 | Cytoplasmic Potential | ||||||
| Transmembrane | 390 – 410 | 21 | Helical; Potential | ||||||
| Topological domain | 411 – 419 | 9 | Extracellular Potential | ||||||
| Transmembrane | 420 – 440 | 21 | Helical; Potential | ||||||
| Topological domain | 441 – 450 | 10 | Cytoplasmic Potential | ||||||
| Transmembrane | 451 – 471 | 21 | Helical; Potential | ||||||
| Topological domain | 472 – 478 | 7 | Extracellular Potential | ||||||
| Transmembrane | 479 – 499 | 21 | Helical; Potential | ||||||
| Topological domain | 500 – 545 | 46 | Cytoplasmic Potential | ||||||
Amino acid modifications | |||||||||
| Glycosylation | 39 | 1 | N-linked (GlcNAc...) Potential | ||||||
| Glycosylation | 56 | 1 | N-linked (GlcNAc...) Ref.7 | ||||||
| Glycosylation | 86 | 1 | N-linked (GlcNAc...) Ref.7 | ||||||
| Glycosylation | 91 | 1 | N-linked (GlcNAc...) Ref.7 | ||||||
| Glycosylation | 107 | 1 | N-linked (GlcNAc...) Ref.7 | ||||||
| Glycosylation | 178 | 1 | N-linked (GlcNAc...) Potential | ||||||
Experimental info | |||||||||
| Mutagenesis | 39 | 1 | N → Q: Complete loss of PAH transport activity. Ref.7 | ||||||
| Mutagenesis | 49 | 1 | C → A: Decrease in the level of cell surface expression and transport function. Complete loss of transport function; when associated with A-78; A-99; A-122; A-172; A-183; A-200; A-362; A-335; A-379; A-402; A-427 and A-434. Ref.1 | ||||||
| Mutagenesis | 122 | 1 | C → A: Decrease in the level of cell surface expression and transport function. Complete loss of transport function; when associated with A-49; A-78; A-99; A-172; A-183; A-200; A-362; A-335; A-379; A-402; A-427 and A-434. Ref.1 | ||||||
| Mutagenesis | 183 | 1 | C → A: Decrease in the level of cell surface expression and transport function. Complete loss of transport function; when associated with A-49; A-78; A-99; A-122; A-172; A-200; A-362; A-335; A-379; A-402; A-427 and A-434. Ref.1 | ||||||
| Mutagenesis | 434 | 1 | C → A: Decrease in the level of cell surface expression and transport function. 80% decrease in the level of transport activity; when associated with A-49; A-122 and A-183. Complete loss of transport function; when associated with A-49; A-78; A-99; A-122; A-172; A-183; A-200; A-362; A-335; A-379; A-402 and A-427. Ref.1 | ||||||
| Sequence conflict | 66 | 1 | W → R in AAC53112. Ref.1 | ||||||
Sequences
| ||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "Molecular cloning and characterization of NKT, a gene product related to the organic cation transporter family that is almost exclusively expressed in the kidney." Lopez-Nieto C.E., You G., Bush K.T., Barros E.J., Beier D.R., Nigam S.K. J. Biol. Chem. 272:6471-6478(1997) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, MUTAGENESIS OF CYS-49; CYS-78; CYS-99; CYS-122; CYS-172; CYS-183; CYS-200; CYS-326; CYS-335; CYS-379; CYS-402; CYS-427 AND CYS-434, SUBCELLULAR LOCATION. Strain: BALB/c. Tissue: Kidney. |
| [2] | "The transcriptional landscape of the mammalian genome." Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N., Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K., Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J. Hayashizaki Y.Science 309:1559-1563(2005) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. Strain: C57BL/6J. Tissue: Cerebellum. |
| [3] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. Strain: FVB/N. Tissue: Liver. |
| [4] | "Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells." Kuze K., Graves P., Leahy A., Wilson P., Stuhlmann H., You G. J. Biol. Chem. 274:1519-1524(1999) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, TISSUE SPECIFICITY. |
| [5] | "Regulation of mOAT-mediated organic anion transport by okadaic acid and protein kinase C in LLC-PK(1) cells." You G., Kuze K., Kohanski R.A., Amsler K., Henderson S. J. Biol. Chem. 275:10278-10284(2000) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION. |
| [6] | "Cysteine residues in the organic anion transporter mOAT1." Tanaka K., Zhou F., Kuze K., You G. Biochem. J. 380:283-287(2004) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION. |
| [7] | "Role of glycosylation in the organic anion transporter OAT1." Tanaka K., Xu W., Zhou F., You G. J. Biol. Chem. 279:14961-14966(2004) [PubMed] [Europe PMC] [Abstract] Cited for: MUTAGENESIS OF ASN-39, GLYCOSYLATION AT ASN-56; ASN-86; ASN-91 AND ASN-107. |
| + | Additional computationally mapped references. |
Cross-references
Sequence databases | |
|---|---|
| EMBL GenBank DDBJ | U52842 mRNA. Translation: AAC53112.1. AK035971 mRNA. Translation: BAC29261.1. BC021647 mRNA. Translation: AAH21647.1. |
| IPI | IPI00310736. |
| RefSeq | NP_032792.2. NM_008766.3. |
| UniGene | Mm.30090. |
3D structure databases | |
| ProteinModelPortal | Q8VC69. |
| ModBase | Search... |
Proteomic databases | |
| PaxDb | Q8VC69. |
| PRIDE | Q8VC69. |
Protocols and materials databases | |
| StructuralBiologyKnowledgebase | Search... |
Genome annotation databases | |
| Ensembl | ENSMUST00000010250; ENSMUSP00000010250; ENSMUSG00000024650. |
| GeneID | 18399. |
| KEGG | mmu:18399. |
| UCSC | uc008gme.2. mouse. |
Organism-specific databases | |
| CTD | 9356. |
| MGI | MGI:892001. Slc22a6. |
Phylogenomic databases | |
| eggNOG | COG0477. |
| GeneTree | ENSGT00550000074177. |
| HOGENOM | HOG000234569. |
| HOVERGEN | HBG108433. |
| InParanoid | Q8VC69. |
| KO | K08203. |
| OMA | APFFAFF. |
| OrthoDB | EOG418BPG. |
Gene expression databases | |
| Bgee | Q8VC69. |
| Genevestigator | Q8VC69. |
Family and domain databases | |
| InterPro | IPR020846. MFS_dom. IPR016196. MFS_dom_general_subst_transpt. IPR004749. Orgcat_transp. IPR005828. Sub_transporter. [Graphical view] |
| Pfam | PF00083. Sugar_tr. 1 hit. [Graphical view] |
| SUPFAM | SSF103473. MFS_gen_substrate_transporter. 1 hit. |
| TIGRFAMs | TIGR00898. 2A0119. 1 hit. |
| PROSITE | PS50850. MFS. 1 hit. [Graphical view] |
| ProtoNet | Search... |
Other | |
| BindingDB | Q8VC69. |
| ChEMBL | CHEMBL5653. |
| ChiTaRS | SLC22A6. mouse. |
| NextBio | 294008. |
| SOURCE | Search... |
Entry information
| Entry name | S22A6_MOUSE | ||||||||
| Accession | Primary (citable) accession number: Q8VC69 Secondary accession number(s): Q61185 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation program | Chordata Protein Annotation Program | ||||||||
Relevant documents
| MGD cross-references Mouse Genome Database (MGD) cross-references in UniProtKB/Swiss-Prot |
| SIMILARITY comments Index of protein domains and families |

Clusters with
